Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.

Agnihotri S, Aldape KD, Zadeh G.

Neurosurg Focus. 2014 Dec;37(6):E13. doi: 10.3171/2014.9.FOCUS14505.

PMID:
25434382
[PubMed - in process]
2.

The evolving role of molecular markers in the diagnosis and management of diffuse glioma.

Huse JT, Aldape KD.

Clin Cancer Res. 2014 Nov 15;20(22):5601-11. doi: 10.1158/1078-0432.CCR-14-0831.

PMID:
25398843
[PubMed - in process]
3.

C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.

Cachia D, Wani K, Penas-Prado M, Olar A, McCutcheon IE, Benjamin RS, Armstrong TS, Gilbert MR, Aldape KD.

Brain Tumor Pathol. 2014 Nov 12. [Epub ahead of print]

PMID:
25388523
[PubMed - as supplied by publisher]
4.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; on behalf of the MD Anderson Community Clinical Oncology Program and the Brain Tumor Trials Collaborative.

Neuro Oncol. 2014 Sep 19. pii: nou155. [Epub ahead of print]

PMID:
25239666
[PubMed - as supplied by publisher]
5.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

PMID:
25163906
[PubMed - in process]
6.

Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma.

Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.

J Invest Dermatol. 2014 Aug 22. doi: 10.1038/jid.2014.366. [Epub ahead of print]

PMID:
25148578
[PubMed - as supplied by publisher]
7.

Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.

Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, DeMonte F, Fuller GN, Aldape KD.

Brain Pathol. 2014 Jul 18. doi: 10.1111/bpa.12174. [Epub ahead of print]

PMID:
25040885
[PubMed - as supplied by publisher]
8.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

PMID:
24997140
[PubMed - in process]
9.

Lambrolizumab induced central nervous system (CNS) toxicity.

Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW.

J Neurol Sci. 2014 Sep 15;344(1-2):229-31. doi: 10.1016/j.jns.2014.06.023. Epub 2014 Jun 20. No abstract available.

PMID:
24980937
[PubMed - in process]
10.

Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.

Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C.

Oncotarget. 2014 Apr 30;5(8):2208-20.

PMID:
24809734
[PubMed - in process]
Free PMC Article
11.

Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA.

Clin Cancer Res. 2014 Nov 1;20(21):5537-46. doi: 10.1158/1078-0432.CCR-13-3003. Epub 2014 May 6.

PMID:
24803579
[PubMed - in process]
12.

Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.

Kim BY, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE.

J Neurooncol. 2014 Jun;118(2):405-12. doi: 10.1007/s11060-014-1451-0. Epub 2014 Apr 29.

PMID:
24777756
[PubMed - in process]
13.

GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.

Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, Aldape KD, Zadeh G.

Neuro Oncol. 2014 Sep;16(9):1167-75. doi: 10.1093/neuonc/nou035. Epub 2014 Mar 18.

PMID:
24642524
[PubMed - in process]
14.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.

Breast Cancer Res. 2014 Mar 14;16(2):R25. doi: 10.1186/bcr3625.

PMID:
24625110
[PubMed - in process]
Free PMC Article
15.

Molecular subtypes of glioblastoma are relevant to lower grade glioma.

Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS.

PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014.

PMID:
24614622
[PubMed - in process]
Free PMC Article
16.

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis T, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, Agnihotri S, Cavalli FM, Clarke I, Nethery-Brokx K, Creasy CL, Verma SK, Koster J, Wu X, Yao Y, Milde T, Sin-Chan P, Zuccaro J, Lau L, Pereira S, Castelo-Branco P, Hirst M, Marra MA, Roberts SS, Fults D, Massimi L, Cho YJ, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Muraszko KM, Kool M, Pomeroy SL, Gupta N, Phillips J, Huang A, Tabori U, Hawkins C, Malkin D, Kongkham PN, Weiss WA, Jabado N, Rutka JT, Bouffet E, Korbel JO, Lupien M, Aldape KD, Bader GD, Eils R, Lichter P, Dirks PB, Pfister SM, Korshunov A, Taylor MD.

Nature. 2014 Feb 27;506(7489):445-50. doi: 10.1038/nature13108. Epub 2014 Feb 19.

PMID:
24553142
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.

N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

PMID:
24552317
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

PMID:
24470557
[PubMed - indexed for MEDLINE]
19.

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP.

Neuro Oncol. 2014 Jan;16(1):81-91. doi: 10.1093/neuonc/not159. Epub 2013 Dec 4.

PMID:
24305719
[PubMed - indexed for MEDLINE]
20.

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.

Neuro Oncol. 2014 Jan;16(2):173-8. doi: 10.1093/neuonc/not229. Epub 2013 Dec 4. Review.

PMID:
24305708
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk